Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia, Journal of Oncology Pharmacy Practice, December 2018, SAGE Publications,
DOI: 10.1177/1078155218816768.
You can read the full text:

Read

Contributors

The following have contributed to this page